Navigation Links
Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
Date:11/6/2008

WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc., (Amex: ILI), announced today that it will host a conference call and webcast on Thursday, November 13, 2008, at 4:30 pm EST to review the Company's third quarter 2008 financial results and provide an update on recent corporate developments.

To access the live call, dial 877-675-4756 (domestic) or 719-325-4902 (international). The live webcast and replay access of the teleconference will be available on the Investors section of the Company's website at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit http://www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
2. Interleukin-12 indicates survival prospects for melanoma patients
3. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
4. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
5. T cell immunity enhanced by timing of interleukin-7 therapy
6. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
7. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
8. Penn scientists map molecular regulation of fat-cell genetics
9. DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results
10. Genetics, Environment Shape Sexual Behavior
11. Homosexual behavior due to genetics and environmental factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
Breaking Medicine Technology: